Readers will discover the diverse potential applications of TAF in chronic hepatitis B, informed by valuable lessons learned from HIV treatment while also gaining insights into future therapeutic possibilities. Authored by leading experts in the field, each chapter presents focused and insightful perspectives, making this book an indispensable resource for practitioners and researchers alike. Serving as a critical resource for physicians, researchers, pharmacologists, and biomedical scientists, this book highlights the core knowledge necessary for understanding TAF and its clinical applications.
Table of Contents
1. Introduction to Hepatitis B and Current Therapeutic Strategies2. Pharmacological Profile of Tenofovir Alafenamide and mechanisms of action of TAF
3. Comparative Efficacy of TAF Versus Traditional Antiviral Agents: Data from Clinical Trials and Real-World Studies
4. Safety and Tolerability of Tenofovir Alafenamide
5. Impact of TAF on Drug Resistance in Hepatitis B
6. Long-Term Effects of TAF on Liver-related Outcomes and Health
7. TAF in Special Populations part 1: Pediatrics, Elderly, Pregnancy, Immunosuppressed populations
8. TAF in Special Populations part 2: Hepatic impairment and co-infections
9. TAF in Special Populations part 3: Renal impairment
10. Future Directions in Hepatitis B Treatment and the Role of TAF
Authors
Lung-Yi Loey Mak Queen Mary Hospital, China.Dr. Mak is a Clinical Assistant Professor at the University of Hong Kong. She is a hepatologist and clinical researcher focusing on hepatitis B and steatotic liver disease. She has published >150 articles in reputable journals (Google scholar H-index 34). She is an associate editor for Clinical Molecular Hepatology and editorial board member for Hepatology Communications. She has received the Emerging Leader Award by EASL in 2023 and is a member of the Emerging Leaders Committee, Asian Pacific Association of Gastroenterology.
Man-Fung Yuen Queen Mary Hospital, China.Professor Yuen is the Chair Professor of The University of Hong Kong. He is one of the top internationally renowned researchers in the field of hepatitis B disease (Google scholar H-index 115). As a world-class clinician scientist, Professor Yuen is now leading most of the international trials examining new drugs including antiviral and immunomodulatory agents for the treatment of chronic hepatitis B.
